BIOGEN COMPLETES SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO FDA FOR ADUCANUMAB AS A TREATMENT FOR ALZHEIMER?S DISEASE
July 8, 2020 at 7:30 AM EDT
- If approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimer?s disease
Contacts | |
MEDIA CONTACT: Biogen Inc. David Caouette + 617 679 4945 public.affairs@biogen.com INVESTOR CONTACT: Biogen Inc. Joe Mara +781 464 2442 IR@biogen.com | MEDIA CONTACT: Eisai Co., Ltd. Public Relations Department TEL: +81-(0)3-3817-5120 Eisai Inc. Public Relations Department TEL: +1-551-262-2686 INVESTOR CONTACT: Eisai Co., Ltd. Investor Relations Department TEL: +81-(0)3-3817-5327 |